H.C. Wainwright lowered the firm’s price target on Neurogene to $51 from $55 and keeps a Buy rating on the shares post the Q1 report. The analyst expects positive efficacy data for NGN-401 in Q4 and says competitor datasets are likely to be catalysts.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Inc. Optimistic on NGN-401 Trial Progress
- Neurogene reports Q1 EPS ($1.00), consensus ($1.13)
- Neurogene Reveals Encouraging Gene Therapy Trial Results
- Neurogene reports data from Phase 1/2 gene therapy clinical trial for NGN-401
- Apple upgraded, Tesla downgraded: Wall Street’s top analyst calls